Summary:

The company reported another solid quarter with earnings coming in ahead of expectations. Sales grew by 7% excluding currency and 3% on an organic basis. Adjusted earnings per share increased by 20% due to strong operating performance and a lower tax rate. The adjusted operating margin in the second quarter was 10.8%, up slightly versus the prior year. Year-to-date, free cash flow decreased by $59 million compared to the same period last year. The company's balance sheet remains strong, with ample capacity to invest in the business and return cash to shareholders in a disciplined manner. The acquisitions of Yongle and Finesse Medical are expected to have a positive impact on earnings per share. The outlook for the year has been raised, with an updated range of $475 million to $490 million for adjusted earnings per share. Sales growth is expected to be 7% to 8% for the full year, with a lower tax rate of approximately 28%. The company continues to focus on driving productivity and margin improvement across its segments. The impact of currency and commodity costs on margins is relatively modest, and price adjustments are being made as necessary. Working capital ratios are expected to remain relatively similar, with inventory levels starting out at a higher level and gradually being brought back down. Overall, the company is pleased with its progress against its long-term strategic and financial objectives. It continues to pursue a disciplined capital allocation strategy and remains confident in its future outlook.